News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
20,228 Results
Type
Article (1143)
Company Profile (2)
Press Release (19083)
Section
Business (11303)
Career Advice (8)
Deals (1362)
Drug Delivery (2)
Drug Development (1661)
FDA (335)
Job Trends (431)
News (14029)
Policy (628)
Tag
Academia (15)
Allergies (1)
Alliances (864)
ALS (10)
Alzheimer's disease (30)
Antibody-drug conjugate (ADC) (4)
Approvals (346)
Artificial intelligence (2)
Automation (1)
Bankruptcy (3)
Best Places to Work (343)
Biosimilars (3)
Biotechnology (1)
Bladder cancer (6)
Brain cancer (3)
Breast cancer (9)
Cancer (88)
Cardiovascular disease (3)
Career advice (8)
Cell therapy (3)
Clinical research (1505)
Collaboration (10)
Compensation (15)
COVID-19 (31)
C-suite (3)
Cystic fibrosis (2)
Data (91)
Depression (2)
Diabetes (5)
Diagnostics (224)
Digital health (1)
Drug discovery (3)
Drug pricing (2)
Drug shortages (1)
Earnings (10290)
Events (1062)
Executive appointments (4)
FDA (476)
Friedreich's ataxia (1)
Frontotemporal dementia (1)
Funding (9)
Gene editing (2)
Gene therapy (2)
GLP-1 (11)
Government (35)
Guidances (110)
Healthcare (558)
Huntington's disease (1)
IgA nephropathy (3)
Immunology and inflammation (6)
Indications (1)
Infectious disease (32)
Inflammatory bowel disease (2)
Intellectual property (3)
IPO (996)
Job creations (111)
Job search strategy (8)
Labor market (1)
Layoffs (6)
Legal (127)
Lung cancer (18)
Lymphoma (13)
Manufacturing (7)
MASH (1)
Medical device (512)
Medtech (512)
Mergers & acquisitions (381)
Metabolic disorders (13)
Multiple sclerosis (1)
Neurodegenerative disease (3)
Neuropsychiatric disorders (3)
Neuroscience (51)
NextGen: Class of 2025 (139)
Non-profit (23)
Obesity (8)
Opinion (6)
Ovarian cancer (2)
Pancreatic cancer (1)
Parkinson's disease (2)
Patents (3)
Patient recruitment (3)
People (773)
Pharmaceutical (1)
Pharmacy benefit managers (1)
Phase I (348)
Phase II (581)
Phase III (686)
Pipeline (316)
Postmarket research (61)
Preclinical (104)
Press Release (2)
Prostate cancer (4)
Radiopharmaceuticals (6)
Rare diseases (13)
Real estate (121)
Regulatory (505)
Reports (1)
Research institute (20)
Schizophrenia (1)
Series A (1)
Series B (1)
Sickle cell disease (2)
Special edition (2)
Spinal muscular atrophy (1)
Startups (59)
Tariffs (1)
Vaccines (12)
Venture capital (1)
Weight loss (5)
Women's health (1)
Date
Today (1)
Last 7 days (5)
Last 30 days (35)
Last 365 days (1165)
2025 (880)
2024 (1381)
2023 (1554)
2022 (1701)
2021 (1619)
2020 (1313)
2019 (949)
2018 (783)
2017 (6020)
2016 (347)
2015 (551)
2014 (350)
2013 (182)
2012 (241)
2011 (281)
2010 (273)
Location
Africa (19)
Alabama (2)
Arizona (8)
Asia (1192)
Australia (170)
California (314)
Canada (116)
China (22)
Colorado (17)
Connecticut (16)
Delaware (8)
Europe (2984)
Florida (75)
Georgia (9)
Illinois (18)
India (1)
Indiana (20)
Japan (9)
Kansas (5)
Kentucky (1)
Louisiana (5)
Maine (5)
Maryland (35)
Massachusetts (265)
Michigan (16)
Minnesota (24)
Missouri (8)
Montana (1)
Nevada (2)
New Hampshire (2)
New Jersey (126)
New York (70)
North Carolina (40)
Northern California (136)
Ohio (7)
Pennsylvania (63)
South America (25)
Southern California (144)
Tennessee (3)
Texas (41)
United States (1245)
Utah (19)
Virginia (3)
Washington D.C. (1)
Washington State (33)
Wisconsin (4)
20,228 Results for "166".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
September 23, 2025
·
6 min read
Press Releases
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
September 18, 2025
·
8 min read
Press Releases
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
April 9, 2025
·
5 min read
Biotech Beach
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
MediciNova, Inc. announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166.
May 7, 2024
·
4 min read
Biotech Beach
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis of eye cancer.
May 20, 2024
·
6 min read
Policy
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis in various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, and ovarian cancer.
June 5, 2024
·
5 min read
Biotech Beach
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the treatment of chlorine-induced acute respiratory distress syndrome.
May 14, 2024
·
5 min read
Biotech Beach
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
MediciNova, Inc. today announced it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.
March 26, 2024
·
5 min read
Drug Development
OcuTerra Announces Topline Data from Phase 2 DR:EAM Trial Evaluating Nesvategrast (OTT166 5%) for Patients with Diabetic Retinopathy
OcuTerra Therapeutics, Inc. today announced topline results from its Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast (OTT166), a novel, selective RGD integrin inhibitor developed as an eye drop.
March 14, 2024
·
5 min read
Biotech Beach
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
MediciNova, Inc. announced that an abstract regarding results of a clinical trial of MN-166 in glioblastoma has been selected for an oral presentation at the American Society of Clinical Oncology Annual Meeting to be held May 31 – June 4, 2024 in Chicago.
April 2, 2024
·
5 min read
1 of 2,023
Next
